Article

The DNA repair pathway as a therapeutic target to synergize with trastuzumab deruxtecan in HER2-targeted antibody-drug conjugate–resistant HER2-overexpressing breast cancer

2023-05-17

Abstract excerpt

<title>Abstract</title> <p><bold>Background: </bold>Anti-HER2 therapies, including the HER2 antibody-drug conjugates trastuzumab emtansine (T-DM1) and trastuzumab deruxtecan (T-DXd), have improved survival outcomes for patients with HER2-overexpressing/amplified (HER2+) metastatic breast cancer. However, intrinsic or acquired resistance to anti-HER2–based therapies remains a clinical challenge for HER2+ metastati...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 00ec8023-44b1-5da9-870e-6ba24412f52c
DOI: 10.21203/rs.3.rs-2918702/v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

The DNA repair pathway as a therapeutic target to synergize with trastuzumab deruxtecan in HER2-targeted antibody-drug conjugate–resistant HER2-overexpressing breast cancerDOI 10.21203/rs.3.rs-2918702/v1Read

Mechanism of action and resistance to Trastuzumab Deruxtecan in patients with metastatic breast cancer: the DAISY trialSemantic proximity Read

An anti-EGFR antibody-drug conjugate overcomes resistance to HER2-targeted drugsSemantic proximity Read

Response to trastuzumab-deruxtecan in metastatic triple-negative breast cancer with both HER2 mutation and low expression.Semantic proximity Read

DNA damage response inhibitors: An avenue for TNBC treatment.Semantic proximity Read

Comprehensive Profiling of DNA Repair Defects in Breast Cancer Identifies a Novel Class of Endocrine Therapy Resistance DriversSemantic proximity Read

Investigating mechanisms of acquired drug resistance in Triple Negative Breast CancerSemantic proximity Read

AKR1C mediates the acquired resistance to T-Dxd in a HER-2 positive gastric cancer lineSemantic proximity Read

[Trastuzumab Deruxtecan for EGFR-mutant Lung Adenocarcinoma with Acquired High-level HER2 Amplification: A Case Report].Semantic proximity Read

Effects of Ado-Trastuzumab Emtansine and Fam-Trastuzumab Deruxtecan on Metastatic Breast Cancer Harboring HER2 Amplification and the L755S Mutation.Semantic proximity Read

Dual HER2/HER3 Targeting with Antibody-Drug Conjugates Reveals a Novel Therapeutic Strategy for HER2-Mutant Lobular Breast CancerSemantic proximity Read

Exploiting DNA repair defects in triple negative breast cancer to improve cell killingSemantic proximity Read

Translational insights and overall survival in the U31402-A-U102 study of patritumab deruxtecan (HER3-DXd) in EGFR-mutated NSCLC.Semantic proximity Read